Peer-reviewedCC BY-NCJournal of Clinical and Translational Hepatology
The CYB5R3–mARC1 Redox Axis in Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanistic Basis and Therapeutic Prospects across the Steatosis–Cirrhosis–Hepatocellular Carcinoma Spectrum
Related
- The cGAS-STING pathway in metabolic dysfunction-associated steatotic liver disease: mechanistic insights and therapeutic opportunities
- Ultra-Processed Food Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evidence Synthesis, Methodological Appraisal, and Mechanistic Insights
- Hypoxia-inducible factor-1α–mediated metabolic reprogramming in sepsis-associated organ dysfunction: organ-specific metabolic mismatch and therapeutic perspectives
- Targeting Gut Microbiota, Inflammation, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: Therapeutic Strategies and the Emerging Role of Time-Restricted Feeding
- Multiomics, multi-species profiling, and animal validation identify mitoxyperilysis as a conserved therapeutic target in metabolic dysfunction-associated steatohepatitis.
BibTeX
@article{anon2026cyb5r3marc1,
title = {{The CYB5R3–mARC1 Redox Axis in Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanistic Basis and Therapeutic Prospects across the Steatosis–Cirrhosis–Hepatocellular Carcinoma Spectrum}},
journal = {Journal of Clinical and Translational Hepatology},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13655723},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - The CYB5R3–mARC1 Redox Axis in Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanistic Basis and Therapeutic Prospects across the Steatosis–Cirrhosis–Hepatocellular Carcinoma Spectrum
PY - 2026
DA - 2026/09/08
JO - Journal of Clinical and Translational Hepatology
UR - https://europepmc.org/article/PMC/PMC13655723
SN - 2225-0719
ER -